Highlights of the latest releases (v3.1.0- v3.1.1) are: * CPIC function and phenotype assignments are used to provide genotype-level guidance from all sources including DPWG and FDA. For a detailed blog see, Genotype-Phenotype Mapping for Guideline and Drug Label Curation. * Allele definitions are up to date to PharmVar’s  Version 6.2.17.2, which adds new alleles for NAT2, CYP2C19, CYP2C9, SLCO1B1. * Recommendation updates (see full list of gene and drugs included in PharmCAT) * Addition

ClinPGx now uses CPIC/ClinPGx allele function and phenotype mappings and terms for guideline and drug label curation, including the interactive genotype picker tools on DPWG guideline annotation pages. If a DPWG guideline gene is not a CPIC gene, then we will continue to use DPWG mappings based on documents previously downloaded from the KNMP website. The DPWG terms and mapping largely agree with CPIC/ClinPGx across genes, but exceptions are noted on the DPWG mappings page. We will also continue

The FDA-approved label for Xeloda (capecitabine) was updated a week ago to include a boxed warning regarding adverse reactions in patients with complete DPD deficiency and to "Test patients for genetic variants of DPYD prior to initiating XELODA unless immediate treatment is necessary." This language is new. The previous version of the label recommended against using the drug "in patients known to have certain homozygous or compound heterozygous DPYD variants that result in complete DPD deficie

The CPIC Guideline for NAT2 Genotype and Hydralazine Therapy has been published in the journal Clinical Pharmacology and Therapeutics. This new guideline summarizes and evaluates literature evidence regarding the impact of genetic variants on NAT2's metabolism of hydralazine, a vasodilator typically used in the treatment of resistant hypertension and heart failure, into inactive metabolites. This is the first CPIC guideline for NAT2 (N-acetyltransferase 2). From the guideline: "NAT2 poor metabol

We are excited to announce the publication of Toward an integrated resource for pharmacogenomics (PGx): Survey findings from the genomic medicine communities (PMID: 40662343) by the ClinGen Pharmacogenomics Interpretation Committee (PGxIC) in Genetics in Medicine. This publication covers the results of the PGxIC’s two needs assessment surveys targeting both the pharmacogenomics and genomic medicine communities, and can be read at this link free of charge until October 2, 2025. We thank all of

We’re excited to announce that our latest paper, titled “Towards an Integrated Resource for Pharmacogenomics (PGx): Survey Findings from the Genomic Medicine Communities,” is now in press in Genetics in Medicine! This work, conducted by the ClinGen Pharmacogenomics Interpretation Committee (PGxIC, formerly the PGx Working Group), presents findings from two community surveys that gathered perspectives from over 500 participants across the PGx and genomic medicine communities. The goal of the sur

Nearly two years ago, we introduced the vision for ClinPGx to integrate the PharmGKB, CPIC and PharmCAT projects into a unified resource. In June 2024, we launched the ClinPGx blog and held the first ClinPGx Meeting. We are excited to announce that over the coming weeks, PharmGKB will officially become ClinPGx. Once the new ClinPGx website debuts, there will be a brief period where both websites will co-exist.  At the end of this period, PharmGKB URLs will automatically redirect users to the eq

PharmGKB is conducting a survey designed to gather user feedback to enhance our content, features and tools. Your insights are essential as PharmGKB transitions to ClinPGx this summer and we prepare our next grant application to support our ongoing project. We would be incredibly grateful for your thoughts on the relevance and value of the PharmGKB website. The survey is designed to be quick and easy, consisting of two parts: (1) a brief section that takes approximately 1 minute to complete, an

We are excited to announce that we have partnered with Dr. Emily Cicali on behalf of The University of Florida Health Precision Medicine Program to incorporate the information presented in the PROPTM pharmacogenetics calculator into the GSI. Users can select from a list of concomitant medications that are either strong or moderate CYP2D6 inhibitors to account for CYP2D6 phenoconversion. Additionally, the following updates have been made: * Users can now enter gene phenotypes as input as well